Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer | Zendy

Huawei Cheng | Zendy; Hongyue Liu | Zendy; Qiong Du | Zendy; Hui Zhang | Zendy; Xiaodan Zhang | Zendy; Yangkui Wang | Zendy; Jingjing Shao | Zendy; Feng Yang | Zendy; Bo Zhang | Zendy; Jing Shi | Zendy; Yuguo Liu | Zendy; Nan Wu | Zendy; Silu Xu | Zendy; Qing Wei | Zendy; Yancai Sun | Zendy; Qing Zhai | Zendy; Bo Yu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer

Author(s) -

Huawei Cheng,

Hongyue Liu,

Qiong Du,

Hui Zhang,

Xiaodan Zhang,

Yangkui Wang,

Jingjing Shao,

Feng Yang,

Bo Zhang,

Jing Shi,

Yuguo Liu,

Nan Wu,

Silu Xu,

Qing Wei,

Yancai Sun,

Qing Zhai,

Bo Yu

Publication year - 2021

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-20-2140

Subject(s) - gefitinib , medicine , lung cancer , oncology , adverse effect , cancer , epidermal growth factor receptor

Gefitinib is a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It was approved by the U.S. Food and Drug Administration (FDA) for clinical use in 2003. However, gefitinib has only come to China in recent years. Previous studies have not compared the efficacy and safety of domestic and imported gefitinib. Therefore, we conducted this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research